CivilsIASPrep.comHealth activists seek revision of India’s essential medicines list to ensure price cap, availability
What does this development mean for UPSC preparation?
UPSC CSE Context Why in News: Civil society demands revision of India's National List of Essential Medicines NLEM after four year gap, citing WHO updates and missing cancer drugs. Syllabus Connection: GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. E
UPSC CSE Context
Why in News: Civil society demands revision of India's National List of Essential Medicines (NLEM) after four-year gap, citing WHO updates and missing cancer drugs. Syllabus Connection: GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. Exam Relevance: Highlights policy lag in essential medicines, price regulation, and right to health; relevant for health governance and social justice questions. ## Core Issue NLEM not updated since 2022; WHO list revised twice; missing cancer and biologic drugs. Key Development: Working Group on Access to Medicines and Treatments writes to government for urgent NLEM revision. Stakeholders:
- Ministry of Health and Family Welfare
- National Pharmaceutical Pricing Authority (NPPA)
- Patients (especially cancer and diabetes) ## Static Knowledge High-Value Background:
- NLEM is a list of essential medicines used to ensure availability and affordability; inclusion triggers price ceiling by NPPA.
- WHO Model List of Essential Medicines serves as global benchmark, updated every two years. Exam Linkage:
- Useful for questions on health policy, drug pricing, and right to health under Article 21. Concepts in Context:
- Essential medicines: drugs that satisfy priority healthcare needs, selected based on disease prevalence, efficacy, safety, and cost-effectiveness.
- Price ceiling: maximum price set by NPPA for essential medicines to ensure affordability. ## Dynamic Analysis ### Governance
- Four-year delay in NLEM revision indicates bureaucratic inertia and lack of periodic review mechanism.
- Absence of transparent, time-bound process for updating list undermines public health preparedness.
- Conflict of interest concerns if pharmaceutical industry influences list composition. ### Health
- Missing cancer drugs and monoclonal antibodies from NLEM denies patients access to modern treatments.
- Diabetes and cancer patients face higher out-of-pocket expenditure due to absence of price caps.
- India's list includes locally relevant drugs (e.g., TB) but gaps in oncology reflect global standard-of-care lag. ### Constitutional/Legal
- Price control through NLEM is a state obligation to ensure affordable healthcare; non-update weakens this commitment.
- Constitutional duty to protect life includes access to essential medicines; delay has human rights implications. ### Economy
- Price ceiling on essential medicines reduces out-of-pocket spending, crucial for low-income households.
- Non-inclusion of new drugs keeps prices high in private market, increasing financial burden on patients.
- Timely revision can stimulate generic production and competition, lowering costs. ## Mains Value Addition Arguments:
- Periodic revision of NLEM is essential to align with evolving disease burden and medical advancements.
- Price regulation through NLEM is a key tool for achieving Universal Health Coverage.
- Delay disproportionately affects vulnerable populations with chronic diseases like cancer and diabetes.
- India's list need not mirror WHO list but must address critical gaps in life-threatening conditions. Examples:
- 17 active cancer-treating agents and 4 supportive cancer-care medicines on WHO list but missing from NLEM.
- Nine monoclonal antibodies absent from NLEM despite being standard in modern cancer treatment. Data Points:
- NLEM last updated on September 13, 2022.
- WHO list expanded to 523 medicines in 2025 from 384 in India's NLEM. Counterpoints:
- Some deviation from WHO list is legitimate due to India's specific disease burden and cost considerations.
- Frequent revisions may disrupt supply chains and increase administrative burden.
- Price caps could reduce profitability, potentially discouraging production of essential medicines. ## Way Forward
- Establish a statutory timeline for mandatory NLEM revision every two years.
- Ensure transparent, conflict-of-interest-free process involving clinicians, public health experts, and civil society.
- Prioritize inclusion of missing cancer drugs and biologics based on disease burden and global evidence.
- Strengthen NPPA's capacity to enforce price ceilings promptly after NLEM update.
- Link NLEM revision with procurement and supply chain planning to ensure availability in public hospitals.